AngioDynamics Slowly Getting the Pieces Into Place

free biotech news

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

New York device maker AngioDynamics has been struggling for a while, but the company has all elements of a come-back. Experienced investors know that the stock market is largely a forward-looking mechanism for valuing companies, and while AngioDynamics (NSDQ:ANGO) continues to struggle with very real present-day challenges, management has been making a number of steps to restore this company to attractive long-term growth and margins. Thursday’s fiscal first quarter earnings served to highlight both sides of that story, as current market conditions remain difficult, but management continues to make progress on multiple fronts.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC